Sector News

LabCorp to buy Envigo’s non-clinical research services business in $485m deal

April 23, 2019
Life sciences

LabCorp’s Covance Drug Development segment is set to acquire Envigo’s non-clinical research services business, while Envigo’s Research Models Services business will purchase the Covance Research Products business.

LabCorp said that the proposed deals will make the company to pay a net cash of $485m and will add an incremental $156m to revenues on a pro forma 2018 basis.

The deal will allow Envigo to become a pure-play research models and services business, while Covance to expand its global non-clinical drug development capabilities.

LabCorp chairman and CEO David King said: “This unique transaction is part of our strategy to transform drug development, strengthening Covance’s ability to offer comprehensive global non-clinical research services to the biopharma industry.”

The scientific and technical expertise and industry insight of Envigo will help Covance to advance its non-clinical capabilities. Covance facilities in Europe and the US will also allow LabCorp to meet growing requirements of the clients.

The combined Covance non-clinical research business will increase its employee base by nearly one-third, to around 4,200 employees across the globe.

The combined research models and services of both suppliers will allow clients to access best models for their research needs across biopharma, contract research organization industry, government and academia.

Envigo, which is a new branded business, will employ over 1,200 people across the globe.

Via strategic supply agreement, the new Envigo research models and services business and Covance will continue to provide research models and services, as well as full range of models, diets and bedding to the clients.

Subject to labor consultations, regulatory approvals and customary closing conditions, the proposed transactions are expected to be completed within two months.

Envigo president and CEO Dr Adrian Hardy said: “This landmark agreement will provide an enhanced experience to our valued customers across both segments of our company and closely aligns with our vision to work together to build a healthier and safer world.”

LabCorp provides comprehensive clinical laboratory and end-to-end drug development services, while Envigo offers mission-critical products and research services for biopharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations.

Source: PBR

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach